Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APN-sEV
- Development stage
- Preclinical
- Lead developer
- Ciloa
- Modality
- Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
APN-sEV (also known as CILO-101) is a bioengineered small extracellular vesicle (sEV) biotherapeutic developed by Ciloa. The candidate utilizes Ciloa's proprietary platform to incorporate recombinant multimerized native adiponectin onto the surface of sEVs, enabling the activation of the adiponectin receptor pathway. By targeting AdipoR1, AdipoR2, and T-cadherin, APN-sEV is designed to address a range of metabolic and inflammatory conditions, including obesity, type 2 diabetes, metabolic dysfunction-associated steatohepatitis (MASH), cardiovascular diseases, and retinopathies. The program is currently in the preclinical stage of development.
- Other names
- CILO-101CILO101CILO 101
02
Targets
ADIPOR1 (Adiponectin receptor 1)ADIPOR2 (Adiponectin receptor 2)NFKB1 (NF-κB1)
Beyond the preview
Go deeper on APN-sEV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APN-sEV.